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A B S T R A C T   
Point of care detection of SARS-CoV-2 is one pillar in a containment strategy and important to break infection 
chains. Here we report the sensitive, specific and robust detection of SARS-CoV-2 and respective variants of 
concern by the ID NOW COVID-19 device.   
1. Introduction 
The reliable detection of SARS-CoV-2 genomes in clinical specimens 
is one of the most crucial task in the identification of SARS-CoV-2- 
infected patients, which is a precondition of conducting proper patient 
management and breaking infection chains [1]. The gold standard of 
virus diagnostics is the real-time PCR that is highly sensitive, specific 
and quick and can give semi-quantitative results under appropriate 
conditions [2,3]. For the detection of SARS-CoV-2 many in-house 
real-time PCR assays have been published in addition to a plethora of 
ready-to-use commercially available kits [4–9]. Real-time PCR is suit-
able to be run as high-throughput approach which takes between 3 and 
4 h for low numbers of specimens including RNA extraction, but can take 
up to more than a day for high numbers of specimens due to 
pre-analytical procedural steps. However, a well-appointed laboratory 
as well as skilled personnel is required for PCR diagnostics. PCR systems 
based on ready-to-use cartridges have reduced handling and 
time-to-result significantly [10,11]. 
Recently, so-called rapid diagnostic tests (RDTs) have reached a 
status of reliability where they can be applied as self-tests even by non- 
trained personnel [12–14]. Usually these tests are based on lateral flow 
assays that specifically recognize viral proteins and can be assessed 
either visually or with a test-specific device [15]. Commonly, these tests 
take about 15 min after sampling but are not well suited for 
high-throughput applications. Most importantly, when comparing their 
positivity rates to real-time PCR results, these RDTs have an analytical 
sensitivity that is significantly lower than that of real-time PCR [12]. 
Hence, depending on the scenario, the choice of the best diagnostic 
approach for SARS-CoV-2 has to balance sensitivity, time to result, 
throughput and simplicity. 
Recently, beside classical PCR, several assays for the detection of 
SARS-CoV-2 based on the isothermal amplification of viral nucleic acids 
have been developed [16]. The ID-NOW platform also utilizes an 
isothermal nucleic acid amplification reaction for the qualitative 
detection of SARS-CoV-2 viral nucleic acids, which suggests a poten-
tially higher sensitivity compared to lateral flow-based RDTs [17]. The 
time to result is approximately 13 min for negative specimens and even 
less for positive specimens, which is considerably shorter than that of a 
real-time PCR. The throughput is relatively low as each device can only 
process one sample at a time. However, there are settings in which a 
short time to result combined with a relatively high analytical sensitivity 
are preferred to a high sample throughput. To evaluate whether the ID 
NOW COVID-19 test can address these demands, we compared the ID 
NOW COVID-19 test with a standard real-time PCR assay. 
2. Material & methods 
For the evaluation of the ID NOW COVID-19 test, specimens from 
primary diagnostics were used in anonymized form. The study obtained 
ethical approval by the Berliner Ärztekammer (Eth 20/40). These 
specimens comprised dry or wet nasopharyngeal and/or oropharyngeal 
swabs sent to the Robert Koch Institute for PCR diagnostics. Wet swabs 
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were kept in transport media and dry swabs were transferred to 1000 μl 
of PBS. All swabs were vortexed and spun down prior to extraction of 
140 μl of the specimen, using the QIAamp Viral RNA Mini Kit and 
QIAcube Connects with the manual lysis protocol. PCR diagnostics was 
performed as described previously (under review). Remaining specimen 
volume was stored at − 40 ◦C to − 80 ◦C. In total, 179 SARS-CoV-2- 
positive specimens were subjected to the ID NOW COVID-19 test. 
These specimens covered a range of viral loads from 2.3 × 102 to 7.4 ×
108 SARS-CoV-2 genome copies/mL. 
For specificity testing, 36 clinical specimens negative for SARS-CoV- 
2, but sampled successfully as demonstrated by the presence of human 
nucleic acid (c-myc CT values between 26 and 38), were used with a PBS 
background. Furthermore, 40 swab samples taken from various healthy 
persons every second day and intermittently positive controls were 
measured to see whether randomly taken specimens give false-positive 
results. 
In addition, 16 respiratory clinical specimens previously sampled 
from patients with influenza-like illness within the German influenza 
sentinel [18] containing influenza virus A/H1N1 (2009), B/vic, B/yam, 
H3N2, RSV, HMPV, AdV, HRV, PIV-1, PIV-2, PIV-3, PIV-4, HKU1, 
HCoV-229E, -OC43 or -NL63 with CT values between 18 and 27 were 
tested. In total, 92 specimens were analyzed to evaluate the specificity. 
Finally, cell culture supernatants of a reference strain (SARS-CoV-2/ 
Italy-INMI1, kindly provided by Antonino DiCaro via the GHSAG 
network), the B.1.1.7 variant (Robert Koch Institute [RKI] isolate), the 
B.1.351 SA variant (kindly provided by Thorsten Wolff, RKI) and the 
Brazil TY7-503 variant of the P.1 lineage (hCoV-19/Japan/TY7-503/ 
2021, kindly provided by Takaji Wakita, National Institute of Infectious 
Diseases, Japan, via the GHSAG network) grown in Vero E6 cells were 
used to test whether the ID NOW COVID-19 test detects these variants 
with a similar sensitivity as that for the SARS-CoV-2 variants circulating 
during the first months of the pandemic. RNA load was quantified by 
real-time PCR and variant identity confirmed by sequencing. In total, 12 
dilutions (1:2) covering a range of the expected detection limit from 5.5 
× 105 genomes per mL to 300 genomes per mL were generated and 
measured in the ID NOW COVID-19 test. When three consecutive di-
lutions showed negative results, the analysis was stopped. 
3. ID NOW COVID-19 testing 
Testing was performed using the ID NOW™ COVID-19 test (REF 190- 
000; Abbott Diagnostics Scarborough Inc., Scarborough, MA, USA) ac-
cording to the manufacturer’s instructions with the ID NOW™ Instru-
ment (NAT-024; Abbott). Quality control (QC) testing was performed 
prior to sample testing using the positive swab provided (REF 190-415, 
Lot: 123,496) and a negative patient swab. For sample testing, either 50 
μl or 100 μl of the respective sample were added directly to the elution 
buffer of the sample receiver and resuspended carefully. 
4. Results 
None of the 92 specimens PCR negative for SARS-CoV-2 showed a 
positive result when analyzed with the ID NOW COVID-19 test, indi-
cating a high analytical specificity for SARS-CoV-2. One out of 40 swab 
samples of SARS-CoV-2-negative persons showed an invalid result. 
Repetition of the sampling gave a negative result in the following ID 
NOW COVID-19 test. Only one of the 36 clinical specimens with a PBS 
background resulted in an invalid result, which is likely due to the 
cloudiness of the specimen (that was not causing problems in the real- 
time PCR). Clinical specimens containing respiratory viruses as listed 
above remained negative, resulting in an overall specificity of 100%. 
For determination of the detection limit of the ID NOW system, in 
total, 179 clinical specimens positive in the SARS-CoV-2 real-time PCR, 
with CT values between 14.6 (7.4 × 108 genome copies per mL) and 36.4 
(2.3 × 102 genome copies per mL), were subjected to the ID NOW 
COVID-19 test system. One specimen showed an invalid result. Overall, 
of the remaining 178 specimens, 142 were positive with the ID NOW and 
35 specimens were negative (overall sensitivity 80.2%). Considering 
that according to various studies a patient is infectious with a genome 
load of >106 copies per mL [19–21], reflected by a CT value of <24.7 in 
our system (n = 56), the ID NOW has a sensitivity of 100% for poten-
tially infectious specimens. Binary logistic regression revealed a 50% 
detection probability at CT 32.3 (95% CI 31.7 to 33.0) representing 3.7 
× 103 (95% CI 5.7 × 103 to 2.3 × 103) genome copies per mL, with 
individual specimens detected positive containing only 800 genome 
copies per mL (Fig. 1). 
To test whether recently increasingly circulating variants of concern 
(VOC) can be detected with the ID NOW COVID-19 test, we used cell 
culture supernatants of the variants listed above. Genome numbers were 
determined by real-time PCR. Since all analyzed variants show identical 
sequences in the PCR target regions (E-Gene and orf1ab), cross- 
comparison of genome numbers by referring to the CT value is appro-
priate. As shown in Fig. 2, the detectable genome loads are comparable 
between the different VOC B.1.1.7, B.1.351 SA, Brz TY7-503 and the 
reference strain Italy/INMI1. 
5. Discussion 
The ID NOW system is a user-friendly device that does not require 
laboratory skills for an analysis. It is small and can be regarded as a 
mobile test device, even if it is not a classical point of care test based on 
lateral flow assays. The total run time for a negative result is approxi-
mately 13 min and less than 10 min for a positive result. The sample 
throughput is low as each device can only process one sample at a time. 
Apart from this, it shows several advantages compared to common point 
of care tests. The ID NOW system has an analytical sensitivity which is 
close to that of real-time PCR systems. Compared to the reference real- 
time PCR assay used in this study, which can detect down to <200 
genome copies per mL of specimen, the ID NOW has a 50% detection 
probability of 3700 genome copies per mL and can detect down to 800 
genome copies in individual specimens. The specificity of the ID NOW 
system was 100% when SARS-CoV-2-negative specimens were analyzed 
as well as specimens containing respiratory viruses including influenza 
viruses and coronaviruses. 
Considering the turn-around time of a real-time PCR diagnostic test, 
the ID NOW has significant benefits when low sample numbers have to 
Fig. 1. Analytical sensitivity of the ID NOW COVID-19 system as determined by 
binary logistic regression. Positivity rate as well as the 95% CI are plotted vs the 
CT value for each specimen (blue circles). Red stars indicate specimens from 
which SARS-CoV-2 could be grown in cell culture, and the red line shows the 
virus load of 106 genome copies per mL of specimen actually accepted as 
necessary limit for infectious specimens. The green line indicates the 50% 
detection probability. 
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be analyzed. Therefore, all settings in which rapid results for few spec-
imens are required, the ID NOW provides reliable and sensitive results. 
For example, considering that there are medical settings in which a 
patient cannot wear a face-mask, e.g. at the dentist or the otorhinolar-
yngologist, the process of excluding infectivity for this patient would 
take less than 15 min. In addition, the ID NOW offers also the testing for 
influenza A and B, RSV and group A streptococci. Depending on what is 
required, with the option to use swabs directly as well as liquid 
(generated by shaking the swab in buffer), one specimen of a patient 
could be analyzed for additional pathogens, either in parallel by using 
multiple devices or, considering longer time to result, step by step one 
after the other. Summing up, the ID NOW COVID-19 test is a useful piece 
in the puzzle of diagnostic tools that are applied to identify SARS-CoV-2 
infections. 
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Fig. 2. Detectability of SARS-CoV-2 Variants of Concern with the ID NOW 
COVID-19 system. All analyzed VOC can be detected up to CT values that 
represent genome loads below 800 per mL. 
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